Heterotopic ossification after hip arthroplasty: a randomized double-blind multicenter study tenoxicam in 147 hips.
147 patients due to have a cemented total hip arthroplasty were randomized to 4 groups. They received either tenoxicam 20 mg or 40 mg, or placebo, for 5 days or morphine on the day of operation and placebo for 4 days. During the first 5 days 14 patients were excluded. The patients were followed for 1 year, during which another 10 patients were excluded. At follow-up, significantly fewer patients had heterotopic ossifications in the tenoxicam groups than in the placebo and morphine groups. There was no significant difference between the 2 tenoxicam-treated groups, and we therefore conclude that tenoxicam 20 mg for 5 days postoperatively can reduce heterotopic ossification after cemented total hip arthroplasty.
Gebuhr
P
P
Department of Orthopedics, Hvidovre University Hospital, Denmark.
Sletgård
J
J
Dalsgård
J
J
Soelberg
M
M
Keisu
K
K
Hänninen
A
A
Crawford
M
M
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004311:Double-Blind Method; D006622:Hip Prosthesis; D006801:Humans; D009999:Ossification, Heterotopic / Q000517:prevention & control*; D010894:Piroxicam / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control*; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; C032801:tenoxicam